Expertise

Our Investigators

Internationally recognized leaders in the field, PCCTC investigators come from the nation’s top academic medical centers where they are actively engaged in innovative, multidisciplinary prostate cancer research. Leveraging their unique insights into the underlying biology of the disease, our investigators developed the universally adopted clinical states model of prostate cancer and initiated one of the first efforts in oncology to prospectively validate endpoints proposed in definitive phase III trials, PCWG2. The individual research objectives of our investigators are well represented in our clinical trial portfolio and unified by our translational, team-based approach to drug and biomarker development.

Drug Development

The PCCTC selects and prioritizes clinical development opportunities based on our investigators’ unparalleled understanding of the global clinical trials landscape, the strength of the underlying science, and the potential to address critical unmet needs across prostate cancer’s clinical spectrum. Our studies are characterized by close interaction between basic scientists and clinical investigators to optimize the flow of promising agents into early-phase studies, and the complimentary development of novel trial designs, endpoints and predictive biomarkers which ensure the decision to advance or to discontinue a program is made objectively and rapidly. The PCCTC’s Management Team and Scientific Oversight Committee work together to address the scientific, legal, regulatory, database, budgetary, and management concerns of every trial to further accelerate the development of successful drug candidates.

Biomarker Development

A cornerstone of the PCCTC’s research strategy is the co-development of therapies and biomarkers. To transform the clinical management of prostate cancer in the near term, it is essential to develop drugs in more precisely defined and biologically relevant patient groups. The ability to screen for patients most likely to respond to a novel agent is essential for both shortening development timelines and reducing exposure to unnecessary toxicity from ineffective treatment. Following the FDA’s Critical Path Initiative, we initiated one of the first endeavors in oncology to define blood and imaging-based biomarkers, develop analytically valid assays for them, and subsequently design and conduct the dedicated clinical trials necessary to establish their clinical validity. Capitalizing on the intellectual synergy of our investigators, our extensive clinical trial portfolio, and our many resources and basic science collaborations, our long-term objective is to establish intermediate or surrogate endpoints which can predict clinical benefit and form the basis for accelerated drug approvals.

Recent News +++

PCCTC Investigators on the Diversity of Enrollment in Prostate Cancer Clinical Trials

Press Releases by AACR June 5, 2020

“Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Futu...

Learn More

The Transformative Development and Progress of the PCCTC

Press Releases by UroToday May 12, 2020

Dr. Charles Ryan (University of Minnesota) is joined by the PCCTC’s CEO, Jake Vinson...

Learn More

The PCCTC: Addressing Health Disparities by Increasing Diversity in Clinical Trials

Press Releases by CDMRP April 22, 2020

A commitment to addressing prostate cancer health disparities.

Learn More

Prostate Cancer Working Group 3 (PCWG3) Criteria in Clinical Trials

Press Releases by PCCTC April 16, 2020

Dr. Alicia Morgans (Northwestern University Feinberg School of Medicine) welcomes PCCTC Me...

Learn More

CCC19 Registry Launched to Understand COVID-19 in Patients with Cancer

Media Relations by Hannah Slater via CancerNetwork March 27, 2020

All are encouraged to participate to quickly gather details related to patients with cance...

Learn More
View More News +

Follow Us

RT @ChrisSweens1: @Uromigos @ANZUPtrials @TrialsCentre @PCF_Science @CDNCancerTrials @ThePCCTC @cancertrials_ie A conversation on interpret…
Dr. Karen Autio (@sloan_kettering), who has led several trials within the PCCTC, discusses the potential role of ch… https://t.co/kh6H7JMFmL
RT @urotoday: Implementing #ProstateCancer Working Group 3 criteria in #ClinicalTrials. #WatchNow @morr316, Lawrence Schwartz, MD and @CaPs…

Join our team of dedicated clinical research professionals! The Prostate Cancer Clinical Trials Consortium is currently seeking a Quality Manager and Clinical Data Manager to help fulfill our…

2018-23944 Clinical Data Manager, Prostate Cancer Clinical Trials Consortium (PCCTC) | Memorial Sloan Kettering Cancer Center Careers

careers.mskcc.org

Committed to world-class science!

Our services translate scientific discoveries into improved standards of care, ensuring efficient trial selection, reporting, site management, clinical operations and data analyses.